Rosa De Vincenzo

Dr. Rosa De Vincenzo

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1990 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
GSG Scambia
G Scambia
FRFo Ranelletti
Fo Ranelletti
PPP Benedetti Panici
P Benedetti Panici
MPM Piantelli
M Piantelli
GBG Bonanno
G Bonanno
SMS Mancuso
S Mancuso
We investigated the effect of the flavonoid quercetin (Q) on the proliferation of the ovarian cancer cell line OVCA 433. Growth experiments demonstrated that Q exerted a reversible dose-dependent inhibition of cell proliferation in the range of concentrations between 10 nM and 10 microM. Two other flavonoids tested, rutin and hesperidin, were ineffective in inhibiting cell growth. Cell cycle analysis showed that the growth inhibitory effect of Q was due to a blocking effect in the GO/G1 phase. Using a whole cell assay with (6.7-3H) oestradiol (3H-E2) as tracer we demonstrated that OVCA 433 cells contain type II oestrogen binding sites (type II EBS). Competition analysis showed that Q competed for 3H-E2 binding to type II EBS while both rutin and hesperidin did not. Appreciable amounts of type II EBS were also detected in seven primary ovarian tumours. Our results suggest that Q may regulate ovarian cancer cell growth through a mechanism involving a binding interaction with type II EBS. This mechanism could also be active in vivo since primary ovarian tumours contain type II EBS.

1 December 2014 in International Journal of Women's Health
Verified
Journal Article
Open access
Rosa De VincenzoRosa De Vincenzo
Rosa De Vincenzo
CCCarmine Conte
Carmine Conte
CRCaterina Ricci
Caterina Ricci
GSGiovanni Scambia
Giovanni Scambia
GCGiovanni Capelli
Giovanni Capelli
In this paper, we review the published evidence about the long-term efficacy of the available human papillomavirus (HPV) vaccines and their safety profile. Two prophylactic HPV vaccines – bivalent (bHPV) and quadrivalent (qHPV) – are now available, and vaccination programs are being widely implemented, primarily targeting adolescent girls. Efficacy has been widely demonstrated for both vaccines. Since the risk of HPV exposure potentially persists throughout a woman’s sexual life, vaccine duration of protection is critical to overall effectiveness. Interpreting the results of long-term efficacy studies for the two HPV vaccines can be puzzling, due to the heterogeneity of studies, different methods used in the assessment of immunogenicity, histopathological and virological end points, and statistical power issues. Moreover, an immunologic correlate of protection has not yet been established, and it is unknown whether higher antibody levels will really result in a longer duration of protection. Disease prevention remains the most important measure of long-term duration of vaccine efficacy. To date, the longest follow-up of an HPV vaccine has been 9.4 years for the bHPV vaccine. Long-term follow-up for qHPV vaccine goes up to 8 years. The vaccine continues to be immunogenic and well tolerated up to 9 years following vaccination. All randomized controlled clinical trials of the bHPV and the qHPV vaccines provide evidence of an excellent safety profile. The most common complaint reported is pain in the injection site, which is self-limiting and spontaneously resolved. The incidence of systemic adverse events (AEs), serious AEs, and discontinuations due to a serious AE reported in clinical studies are similar between the two vaccines and their control groups. In particular, no increased risk of autoimmune disease has been shown among HPV-vaccinated subjects in long-term observation studies. As these are crucial topics in HPV vaccination, it is important to establish systems for continued monitoring of vaccine immunogenicity, efficacy, and safety over time.

1 July 1991 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
GSG. Scambia
G. Scambia
FRF. O. Ranelletti
F. O. Ranelletti
PPP. Benedetti Panici
P. Benedetti Panici
MPM. Piantelli
M. Piantelli
GBG. Bonanno
G. Bonanno
SMS. Mancuso
S. Mancuso

1 May 1996 in European Journal of Cancer
Verified
Journal Article
Closed access
GSG. Scambia
G. Scambia
Rosa De VincenzoRosa De Vincenzo
Rosa De Vincenzo
PRP.O. Ranelletti
P.O. Ranelletti
PPP. Benedetti Panici
P. Benedetti Panici
Gabriella FerrandinaGabriella Ferrandina
Gabriella Ferrandina
SMS. Mancuso
S. Mancuso

18 March 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Andrea GianniniAndrea Giannini
Andrea Giannini
VDViolante Di Donato
Violante Di Donato
FSFrancesco Sopracordevole
Francesco Sopracordevole
ACAndrea Ciavattini
Andrea Ciavattini
AGAlessandro Ghelardi
Alessandro Ghelardi
GBGiorgio Bogani
Giorgio Bogani
The objective of this work is to assess the 5-year outcomes of patients undergoing conization for high-grade cervical lesions that simultaneously present as risk factors in the persistence of HPV infection and the positivity of surgical resection margins. This is a retrospective study evaluating patients undergoing conization for high-grade cervical lesions. All patients included had both positive surgical margins and experienced HPV persistence at 6 months. Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratio (HR). The charts of 2966 patients undergoing conization were reviewed. Among the whole population, 163 (5.5%) patients met the inclusion criteria, being at high risk due to the presence of positive surgical margins and experiencing HPV persistence. Of 163 patients included, 17 (10.4%) patients developed a CIN2+ recurrence during the 5-year follow-up. Via univariate analyses, diagnosis of CIN3 instead of CIN2 (HR: 4.88 (95%CI: 1.10, 12.41); p = 0.035) and positive endocervical instead of ectocervical margins (HR: 6.44 (95%CI: 2.80, 9.65); p < 0.001) were associated with increased risk of persistence/recurrence. Via multivariate analyses, only positive endocervical instead of ectocervical margins (HR: 4.56 (95%CI: 1.23, 7.95); p = 0.021) were associated with worse outcomes. In this high-risk group, positive endocervical margins is the main risk factor predicting 5-year recurrence.

2 October 2000 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
Rosa De VincenzoRosa De Vincenzo
Rosa De Vincenzo
CFCristiano Ferlini
Cristiano Ferlini
MDMariagrazia Distefano
Mariagrazia Distefano
CGCristiana Gaggini
Cristiana Gaggini
ARAntonella Riva
Antonella Riva
GSGiovanni Scambia
Giovanni Scambia